Sanofi’s Lunsekimig Delivers Strong Phase 2 Wins in Asthma and CRSwNP, Expanding Promise of Dual-Target Respiratory Therapy

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES pha...

April 08, 2026 | Wednesday | News
SonoNeu Emerges from Stealth to Advance Sonogenetics as a Breakthrough Drug-Free Therapeutic Modality

Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged&r...

April 08, 2026 | Wednesday | News
Cocrystal Pharma, Inc. Secures FDA Fast Track for CDI-988, Advancing First Oral Antiviral for Norovirus

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob...

April 07, 2026 | Tuesday | News
Curanex Pharmaceuticals, Inc. Expands Pipeline to Target Cancer Cachexia, Addressing Major Oncology Supportive-Care Gap

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...

April 07, 2026 | Tuesday | News
FDA Extends EYLEA HD Dosing Interval to 20 Weeks, Advancing Long-Term Retinal Care

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...

April 07, 2026 | Tuesday | News
AskBio Completes Enrollment In GenePHIT Phase 2 Trial For AB 1002 In Heart Failure

Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopath...

April 02, 2026 | Thursday | News
Tanner Pharma And Biodexa Partner To Expand Global Access To eRapa For Rare FAP Patients

Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmace...

April 02, 2026 | Thursday | News
Avacta Doses First Patient in FOCUS-01 Trial of AVA6103, Advancing Tumor-Targeted Oncology Platform

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...

April 01, 2026 | Wednesday | News
Viridian Therapeutics Reports Positive Phase 3 REVEAL-1 Data for Elegrobart in Thyroid Eye Disease

REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W a...

March 31, 2026 | Tuesday | News
Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Platform

Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...

March 31, 2026 | Tuesday | News
Eli Lilly and Company Showcases Dual-Therapy Breakthrough in Psoriatic Arthritis and Obesity at AAD 2026

Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...

March 30, 2026 | Monday | News
Novartis to Acquire Excellergy in Up to $2 Billion Deal to Advance Next-Generation Allergy Therapies

Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise o...

March 30, 2026 | Monday | News
Corcept’s Lifyorli™ Becomes First FDA-Approved SGRA for Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endo...

March 27, 2026 | Friday | News
Novo Nordisk and The United Laboratories International Holdings Limited Report Strong Phase 2 Results for Triple Agonist UBT251 in Type 2 Diabetes

  UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nord...

March 26, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close